AI辅助口服小分子新药研发，「知维拓」获数千万元种子轮融资｜36氪首发

Core Insights - Riltide Medicines has completed a seed round financing of several tens of millions of RMB, led by Newell Capital and followed by Qingtan Investment, with funds aimed at advancing preclinical research and developing an AI interactive molecular design platform [1][2] Company Overview - Riltide Medicines, founded in 2024, focuses on AI-driven pharmaceutical development, particularly in innovative oral small molecule drugs targeting autoimmune diseases such as systemic lupus erythematosus and inflammatory bowel disease [1][2] - The CEO, Long Wei, has nearly 20 years of experience in drug development and management, previously holding senior positions at JACOBY Pharmaceuticals and Betta Pharmaceuticals [1] Industry Trends - The AI pharmaceutical sector is witnessing a trend where technological maturity and market expectations are gradually aligning, driven by advancements in generative AI that enhance adaptability across various pharmaceutical applications [2] - The integration of AI technology is becoming essential across all stages of the innovative drug industry, prompting companies to explore how to incorporate AI into existing models [2] Product Development - Riltide Medicines has developed the EnCore AI interactive design platform to accelerate the discovery of lead compounds and enhance molecular optimization efficiency, particularly in the autoimmune field [2] - Oral small molecule drugs are gaining traction as a significant direction for future autoimmune drug development due to their convenience, safety, and lower production costs compared to antibody drugs [2] Investor Perspectives - Newell Capital expresses strong confidence in Riltide Medicines' strategic direction and innovative capabilities in developing oral small molecule drugs for autoimmune diseases, highlighting the team's extensive industry experience and successful track record [3] - Qingtan Investment notes the substantial demand potential in the oral autoimmune disease drug market and believes Riltide Medicines can carve out a unique path in AI-driven drug development [3]